Ankit Mahadevia

2021

In 2021, Ankit Mahadevia earned a total compensation of $4.9M as Chief Executive Officer at Spero Therapeutics, a 130% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$327,618
Option Awards$2,650,765
Salary$590,417
Stock Awards$1,300,000
Other$6,245
Total$4,875,045

Mahadevia received $2.7M in option awards, accounting for 54% of the total pay in 2021.

Mahadevia also received $327.6K in non-equity incentive plan, $590.4K in salary, $1.3M in stock awards and $6.2K in other compensation.

Rankings

In 2021, Ankit Mahadevia's compensation ranked 2,701st out of 12,415 executives tracked by ExecPay. In other words, Mahadevia earned more than 78.2% of executives.

ClassificationRankingPercentile
All
2,701
out of 12,415
78th
Division
Manufacturing
1,064
out of 5,501
81st
Major group
Chemicals And Allied Products
416
out of 2,371
83rd
Industry group
Drugs
363
out of 2,092
83rd
Industry
Pharmaceutical Preparations
239
out of 1,542
85th
Source: SEC filing on August 5, 2022.

Mahadevia's colleagues

We found three more compensation records of executives who worked with Ankit Mahadevia at Spero Therapeutics in 2021.

2021

Satyavrat Shukla

Spero Therapeutics

Chief Financial Officer

2021

Cristina Larkin

Spero Therapeutics

Chief Operating Officer

2021

Tamara Joseph

Spero Therapeutics

Chief Legal Officer

News

In-depth

You may also like